Pharmaceutical composition containing miR-140 and preparation method thereof

By extracting exosomes with high content of miR-140 from auricular chondrocytes, the problem of stably obtaining exosomes of miR-140 is solved, effective treatment of a variety of cancers and osteoarthritis is achieved, and multiple targets are provided The inhibited anti-cancer effects and joint cavity injection exosome preparations significantly improve the therapeutic effect and flexibility.

CN118973591APending Publication Date: 2024-11-15HIROKO SCIENCE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031607.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-28
Filing Date
2023-03-26
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

It is difficult to effectively utilize exosomes of miR-140 as pharmaceutical components in the prior art, especially in terms of stable access and widespread use, especially for the treatment of a variety of cancers and osteoarthritis.

Method used

High-content miR-140-rich exosomes were extracted from auricular chondrocytes, and high-content miR- was prepared by culturing and immortalizing the auricular chondrocytes, combined with exosome release promoters such as monenectin to prepare a high-content miR- 140 exosome pharmaceutical compositions and achieve their therapeutic effects in various diseases by appropriate dosage forms and routes of administration.

Benefits of technology

It has achieved effective treatment of a variety of cancers and osteoarthritis, provided a multi-target inhibition anti-cancer effect, and provided joint cavity injection-type exosome preparations with chondrocyte regeneration ability for osteoarthritis, significantly improving The efficacy and flexibility of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005065252080000061
    Figure BDA0005065252080000061
  • Figure BDA0005065252080000062
    Figure BDA0005065252080000062
  • Figure BDA0005065252080000071
    Figure BDA0005065252080000071
Patent Text Reader

Abstract

[Solution] The present invention provides: a pharmaceutical composition containing, as an active ingredient, an exosome containing a large amount of miR-140; and a method for producing the pharmaceutical composition. [Solution] A pharmaceutical composition comprising an exosome derived from auricular cartilage cells, the exosome comprising miR-140; the method for producing the pharmaceutical composition includes an exosome acquisition step for acquiring exosomes from auricular cartilage cells. The exosome acquisition step includes: an auricular cartilage cell culture step for culturing auricular cartilage cells to obtain cultured cartilage cells; and an exosome collection step in which exosomes are collected from the cultured cartilage cells cultured in the auricular cartilage cell culture step in which an estrogen is included in the culture medium for culturing the auricular cartilage cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a pharmaceutical composition comprising miR-140 and a preparation method thereof. Background Art

[0002] Japanese Patent No. 6726726 describes a pharmaceutical composition having exosomes containing miR-140-3p (claim 2). The exosomes in this publication are recovered from cardiomyocyte-derived cells (CDC). Japanese Patent No. 6035010 and Japanese Patent No. 5395439 also describe a pharmaceutical composition containing miR-140.

[0003] Prior art literature

[0004] Patent Literature

[0005] Patent Document 1: Japanese Patent No. 6726726

[0006] Patent Document 2: Japanese Patent No. 6035010

[0007] Patent Document 3: Japanese Patent No. 5395439 Summary of the invention

[0008] Problems to be solved by the invention

[0009] The object of the present invention is to provide a pharmaceutical composition containing exosomes containing miR-140 as an effective ingredient, and a method for preparing a pharmaceutical composition containing exosomes containing a large amount of miR-140.

[0010] Technical solutions to problems

[0011] The first invention relates to a pharmaceutical composition comprising exosomes derived from auricular chondrocytes, wherein the exosomes contain miR-140.

[0012] The second invention relates to a method for preparing the above-mentioned pharmaceutical composition.

[0013] This method includes an exosome obtaining step of obtaining exosomes from auricular chondrocytes.

[0014] Effects of the Invention

[0015] Provided are a pharmaceutical composition comprising a large amount of miR-140 exosomes as an effective ingredient and a preparation method thereof. DETAILED DESCRIPTION

[0016] The present invention is not limited to the embodiments described below, but includes modifications appropriately made from the embodiments within a range that is obvious to a person skilled in the art.

[0017] The first invention relates to a pharmaceutical composition comprising exosomes derived from auricular chondrocytes, wherein the exosomes contain miR-140.

[0018] Auricular chondrocytes

[0019] The method for collecting auricular chondrocytes is well known, for example, as described in Japanese Patent No. 5320526. The auricular chondrocytes are preferably auricular chondrocytes derived from females.

[0020] Pharmaceutical compositions containing exosomes

[0021] Exosomes are also called exosomes. Exosomes are lipid bilayer membrane particles without a nucleus released by cells. Exosomes contain nucleic acid substances including mRNA or miRNA. For example, Japanese Patent No. 6524162 describes a pharmaceutical composition with mesenchymal stem cell exosomes as an active ingredient. In this way, exosomes are used as an active ingredient in compositions for the treatment or prevention of various diseases.

[0022] miR-140

[0023] MiRNA is a kind of small molecule RNA of 18-22 bases, which binds to mRNA in cells and controls its transcription. MiR-140 (including miR-140-3p, miR-140-5p) is a well-known miR. For example, a miR-140 is recorded in Japanese Patent No. 6948059, Japanese Patent No. 6726726, and Japanese Patent No. 6800470. In addition, pharmaceutical compositions comprising miRNA, for example, as described in Japanese Patent No. 6651061, are well known.

[0024] Target diseases of the pharmaceutical composition

[0025] Examples of target diseases of the pharmaceutical composition, as described in the above patent documents, are solid cancers or tumors. Examples thereof are brain tumors, pharyngeal cancer, maxillary cancer, oral cancer, tongue cancer, lip cancer, thyroid cancer, lung cancer, breast cancer, esophageal cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma, bile duct cancer, pancreatic cancer, renal cell carcinoma, bladder cancer, cervical cancer, uterine cancer, ovarian cancer, skin cancer, malignant melanoma, bone marrow tumors, osteosarcoma, soft tissue tumors, angiosarcoma, and solid tumors in children. The pharmaceutical composition is also believed to be effective for the treatment of osteoarthritis.

[0026] Ingredients of the pharmaceutical composition

[0027] The pharmaceutical composition may also contain a well-known carrier (e.g., water, saline, emulsion, excipient). Also, the pharmaceutical composition may appropriately contain well-known materials. Also, for example, the pharmaceutical composition may also contain well-known anticancer drugs. The pharmaceutical composition may be obtained by mixing the active ingredient with an appropriate carrier.

[0028] The administration route of the pharmaceutical composition of the present invention is not limited, and the composition may be administered systemically or locally.

[0029] The dosage form of the pharmaceutical composition of the present invention can be appropriately determined according to the administration route and is not limited, and examples thereof include injections, drops, tablets, capsules, fine granules, powders, liquids, aqueous solutions dissolved in syrups, patches, suppositories, and the like.

[0030] The subject to which the pharmaceutical composition of the present invention is administered is not limited. For example, the present invention can be used on mammals (humans, pigs, cows, monkeys, baboons, dogs, cats, rats, mice, etc.).

[0031] The method of administration (administration route, dosage, number of administrations per day, timing of administration, etc.) of the subject of the pharmaceutical composition of the present invention is not limited, and a person skilled in the art (e.g., a physician) can appropriately determine it according to the health status of the subject, the degree of the disease, the type of the drug used in combination, etc. An example of the dosage of miR-140 is 1 μg or more and 1 mg or less per day.

[0032] The second invention relates to a method for preparing the above-mentioned pharmaceutical composition, which comprises an exosome obtaining step of obtaining exosomes from auricular chondrocytes.

[0033] A preferred example of the exosome acquisition step includes a culturing step of auricular chondrocytes and a collecting step of exosomes.

[0034] The auricular chondrocyte culture step is a step for culturing auricular chondrocytes to obtain cultured chondrocytes. It is preferred that the culture medium for culturing auricular chondrocytes contains estrogen. Estrogen preferably contains estradiol. Auricular chondrocytes can be obtained, for example, by removing skin, connective tissue, and perichondrium from an auricle obtained from a human body or an animal, and then finely cutting into small pieces of about 5 mm×5 mm, and then separating the auricular chondrocytes by collagenase treatment. The separated auricular chondrocytes can be used directly or used in a pharmaceutical composition after appropriate culture.

[0035] nourish

[0036] Auricular chondrocytes may be cultured using a well-known culture medium and under well-known culture conditions. Of course, it is preferred to add estrogen (especially estradiol) to the culture system.

[0037] The exosome collection step is a step for collecting exosomes from the cultured chondrocytes cultured in the auricular chondrocyte culture step. The exosome collection step preferably includes a step of collecting exosomes from the cultured chondrocytes using monensin or a salt of monensin.

[0038] Collection of exosomes

[0039] Exosomes may be collected according to the method described in Japanese Patent No. 6524162, for example.

[0040] Monensin

[0041] Monensin is a polyether antibiotic isolated from bacteria of the genus Streptomyces. This molecule is widely used as an additive to ruminant feed (trademark Rumensin (registered trademark)) to prevent coccidiosis. Examples of salts of monensin include sodium salt and potassium salt.

[0042] Another example different from the above-described preferred example of the exosome obtaining step includes a culturing step, an immortalizing step, and an exosome collecting step of auricular chondrocytes.

[0043] The immortalization step is a step for immortalizing the cultured chondrocytes cultured in the auricular chondrocyte culture step to obtain immortalized cells.

[0044] Immortality process

[0045] In order to immortalize the cultured chondrocytes, it is sufficient to cause lentiviral infection. For example, the immortalization step preferably includes a step of immortalizing the cultured chondrocytes using SV40 or hTERT. Immortalization using lentivirus is described, for example, in Japanese Patent No. 6302356 and Japanese Patent No. 6868565. It is sufficient to immortalize the cultured chondrocytes by referring to the records of these patent documents and examples.

[0046] In this example, the exosome collection step is a step for collecting exosomes from immortalized cells. The exosome collection step preferably includes a step of collecting exosomes from immortalized cells using monensin or a salt of monensin.

[0047] The present specification also provides a method for treating and a method for preventing a target disease, which comprises the step of administering the above-mentioned pharmaceutical composition to a human body (eg, a patient).

[0048] Example 1

[0049] Immortalization of human auricular chondrocytes

[0050] Lentiviral infection

[0051] Normal female auricle chondrocytes were seeded in a 6-well plate at 30-40% confluence 24 hours before infection.

[0052] The next day, cells were infected with Lenti-SV40 (LV613) and Lenti-hTERT (LV615) lentivirus at an MOI of 5.

[0053] After 72 hours, the cells were passaged and the gene introduction was confirmed by qRT-PCR.

[0054] cDNA was synthesized by extracting RNA from infected and non-infected cells using 5X All-In-One Mastermix and EXCellent CT Lysis Kit (G916).

[0055] Can gene introduction be performed?

[0056] SV40 Forward Primer:

[0057] 5'GACTCAGGGCATGAAACAGG3', (SEQ ID NO: 1)

[0058] SV40 Reverse Primer:

[0059] 5'ACTGAGGGGCCTGAAATGA 3' (SEQ ID NO: 2)

[0060] The cDNA was detected by qRT-PCR.

[0061] As a result, the gene was not introduced into the non-infected cells, but was introduced into the infected cells. The cell morphology of the infected cells was not much different from that of the non-infected cells. However, if the culture was continued, the non-infected cells stopped proliferating at the 15th generation, while the infected cells survived after the 25th generation. From the above, it was concluded that the infection was successful.

[0062] Example 2

[0063] Addition of various exosome release enhancers to immortalized chondrocytes and treatment of culture supernatant

[0064] Immortalized chondrocytes of passage 5 were subcultured and plated at 75 cm 2 Flask, 1.5x10 6The ratio of cells was sown in 4 flasks. 10nM estradiol was added to 3 of them, and 1 was not added, and culture began. On the 4th day of culture, in the flasks added with estradiol, 10uM monensin, 20nM aplimod, and 10uM D609 were added to each flask as an exosome secretion promoter, and the flask without estradiol was used as a control group and cultured until the next day. The next day, the culture medium was collected from each flask, followed by centrifugation at 1,500rpm for 5 minutes. The supernatant was further filtered with a 0.22um filter and stored at -80°C as an exosome component until the analysis of miR was performed.

[0065] Example 3

[0066] Extraction of miR from samples and confirmation of extracted nucleic acid

[0067] Using exoRNAeasy Serum / Plasma Maxi Kit (QIAGEN), microRNA was extracted from the exosome fraction of Example 2. Using a spectrophotometer Nano Drop One (Thermo Fisher Scientific), the A260 / A280 and A260 / A230 of the extracted RNA were measured to confirm that there were no protein and salt inclusions in this sample. The sample was then electrophoresed using an Agilent2100Bioanalyzer (Aligent Technologies) to confirm that only the target nucleic acid was contained. As shown in the table below, it was found that the amount of nucleic acid collected was the largest in the monensin treatment.

[0068] [Table 1]

[0069]

[0070] Example 4

[0071] Extract nucleic acid from samples and synthesize cDNA

[0072] Based on the extracted RNA, cDNA was synthesized using miScript II RT Kit (Catalog No. 218160; QIAGEN) under the following conditions.

[0073] [Table 2]

[0074] cDNA synthesis reaction conditions

[0075]

[0076] ※Replenish to 20uL

[0077] RT time 37℃ 60 points 95℃ 5 points 4℃ ∞

[0078] Example 5

[0079] Exploring miR-140 discovery by real-time PCR

[0080] Based on the cDNA synthesized above, real-time PCR reaction was performed using miScript SYBR Green PCR Kit (Catalog No. 218073, QIAGEN) under the following conditions using a real-time PCR apparatus (LightCycler 480: Roche). At this time, the primer used for miR-140 measurement was Hs_miR-140_1miScript Primer Assay (Cat No. MS00003500; has-miR-140-5p: MIMAT0000431).

[0081] [Table 3]

[0082] PCR reaction conditions

[0083]

[0084] ※Replenish to 25uL

[0085] PCR temperature conditions

[0086]

[0087] As a result, the following values ​​were obtained. Therefore, it was found that the monensin-treated group contained nearly 2 times more miR-140 than the other groups. A low Cp value means that it was detected quickly, which means that a large amount of miR-140 was contained.

[0088] [Table 4]

[0089]

[0090] Investigation

[0091] Previous anticancer drugs showed their anticancer effects by inhibiting one target molecule. On the other hand, new biological substances that act on multiple target molecules with one molecule have begun to be discovered. Among them, micro-RNA (miR) is known to inhibit the transcription or translation of various proteins, and the miR that has shown effective data on inhibiting cancer proliferation in experiments is miR-140. This miR is secreted from cells in the form of exosomes, and its contents are not decomposed in the blood but absorbed by surrounding cells. In the absorbed cells, the biosynthesis of proteins under its control stops. As a result, if this protein is required for the proliferation of cancer, the absorbed cancer cells stop proliferating, which is related to cancer treatment. In addition, exosomes can pass through the blood-brain barrier, so they can also be effectively used for brain-related tumors.

[0092] The increase of miR-140 in various cancer cells has been reported to date, and it has been experimentally effective against a wide range of cancers, including brain tumors, pharyngeal cancer, maxillary cancer, oral cancer, tongue cancer, lip cancer, thyroid cancer, lung cancer, breast cancer, esophageal cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma, biliary tract cancer, pancreatic cancer, renal cell carcinoma, bladder cancer, cervical cancer, uterine cancer, ovarian cancer, skin cancer, malignant melanoma, bone marrow tumors, osteosarcoma, soft tissue tumors, angiosarcoma, and pediatric solid tumors. Here, 42 types of cancer target molecules of miR-140 that play a role have been reported. The cancer target molecules include Muc1, Flap, CTSB, Yes, Wnt-1, Glut1, THY1, GRN, TGFBR, IGF1R, CeMP, Six1, Tripartivemotif28, ORC1, TRPM2, Brd9, cMet, CADM3, PD-L1, ZEB1, mTor, VEGF-A, MMP2, Pin1, HMGN, IL6, ADAMSTS5, IGFBP5, IGF2BP, IP3K, ADAM9, Sox4, Septin2, iASP, ADAM10, ATP8A, PDGFRA, MMO, FGF9, etc. Among them, PD-L1 or VEGF has been used as an antibody cancer drug, and it is estimated that there is a huge difference in effect between inhibiting the action of the molecule with an antibody and inhibiting the biosynthesis of the molecule. Moreover, even for these two target molecules, two expensive antibody drugs are required. In addition, antibody drugs have the major disadvantage that they can only produce antibodies against molecules located outside cells or on the cell surface. On the other hand, this miR / exosome drug can inhibit proteins such as enzymes, transcription factors, and signaling factors that regulate various cancer action points in cells.

[0093] Then, these target molecules required for cancer proliferation, metastasis, and survival are inhibited at one time. Compared with the molecular targeted drugs that were only effective at one point in the past, the possibility of significantly improving the anti-cancer effect is high, and the types of target cancers also involve many types, and the exosomes containing miR-140 that also cross the blood-brain barrier will not decompose before reaching the target organ, so it can become a very effective cancer therapeutic drug. At this time, two methods of administration can be considered. One is intravenous injection, in which case it will migrate to the entire body, but it is believed that the migration rate to the joints of the affected part is low. In the case of cancer treatment, especially in the case of metastasis to the whole body, intravenous injection is applicable considering that it has also metastasized to the brain. However, in the case of no metastasis, local administration to the affected part is preferred.

[0094] On the other hand, the treatment of osteoarthritis, which increases with aging, is mainly symptomatic treatment using analgesics, and a drug for treating the cause of the disease has not yet been developed. However, recently, a decrease in miR-140 has begun to be reported in osteoarthritis. Furthermore, it has been reported that the administration of exosomes containing miR-140 is effective for the recovery of symptoms of osteoarthritis. It is believed that in this administration method for osteoarthritis, administration into the joint cavity is also preferred in order to increase the local concentration.

[0095] The question is where to obtain exosomes containing miR-140 stably. First, it has been reported that articular cartilage produces miR-140, and it has been reported that the administration of exosomes containing miR has a great curative effect on osteoarthritis. Therefore, the inventors collected exosomes containing miR-140 from human auricular chondrocytes, where the discovery of miR-140 has not yet been reported. In addition, since it has been reported that the production of miR-140 is increased by Estradiol (female hormone), the starting chondrocytes are from women. Thus, cells with female hormone receptors are obtained, and the production of miR-140 can be increased by adding female hormones to the culture system. Next, in order to stably collect exosomes from these cells, Lenti-SV40 and Lenti-hTERT are used to immortalize these cells. Finally, in order to collect a large amount of exosomes from these cells, three exosome release promoters are added to collect exosomes, and the amount of miR-140 present at this time is quantified. As a result, a method for causing auricular chondrocytes to express miR-140 in large quantities and stably, which has not been reported so far, was determined. As for miR-140 obtained as described above, exosomes can be stored for a long time under freezing, and therefore have the advantage of being effective as a drug.

[0096] This invention can provide an exosome anticancer preparation that is effective against multiple types of cancer with a single dose, and can provide the first joint cavity-injectable exosome preparation that has chondrocyte regeneration ability for osteoarthritis (OA).

[0097] Industrial Applicability This invention can be applied to the pharmaceutical industry.

Claims

1. A pharmaceutical composition, It is characterized in that The invention comprises exosomes derived from auricular chondrocytes, wherein the exosomes comprise miR-140.

2. A method for preparing a pharmaceutical composition, which is a method for preparing a pharmaceutical composition containing exosomes containing miR-140, It is characterized in that Include: The exosome obtaining step is to obtain the exosomes from auricular chondrocytes.

3. A method for preparing the pharmaceutical composition according to claim 2, It is characterized in that The exosome obtaining step comprises: a step of culturing auricular chondrocytes, wherein the auricular chondrocytes are cultured to obtain cultured chondrocytes; and an exosome collection step of collecting exosomes from the cultured chondrocytes cultured in the auricular chondrocyte culture step, In the auricular chondrocyte culturing step, the medium for culturing the auricular chondrocytes contains estrogen.

4. A method for preparing the pharmaceutical composition according to claim 3, It is characterized in that The estrogen comprises estradiol.

5. The method for preparing the pharmaceutical composition according to claim 3, It is characterized in that The exosome collection step includes a step of collecting exosomes from the cultured chondrocytes using monensin or a salt of monensin.

6. The method for preparing the pharmaceutical composition according to claim 2, It is characterized in that The exosome obtaining step comprises: auricular chondrocyte culturing step, wherein the auricular chondrocytes are cultured to obtain cultured chondrocytes; an immortalization step of immortalizing the cultured chondrocytes cultured in the auricular chondrocyte culture step to obtain immortalized cells; and The exosome collection step is to collect exosomes from the immortalized cells.

7. A method for preparing the pharmaceutical composition according to claim 6, It is characterized in that The immortalization step includes the step of immortalizing the cultured chondrocytes using SV40 or hTERT to obtain immortalized cells.

8. A method for preparing the pharmaceutical composition according to claim 6, It is characterized in that The exosome collection step includes a step of collecting exosomes from the immortalized cells using monensin or a salt of monensin.